Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab combinations in advanced pancreatic cancer
NCT00769483Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2008
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dalotuzumab in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2008; status: completed.
02
Drugs
dalotuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00769483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769483.